A carregar...
A novel targeted immunotherapy for CTCL is on its way: Anti-KIR3DL2 mAb IPH4102 is potent and safe in non-clinical studies
Cutaneous T-cell lymphomas (CTCLs) represent a group of rarely occurring and clinically and pathologically heterogeneous diseases that are considered incurable at advanced stages. Current treatments provide limited clinical benefit and are thus largely amenable to improvement. An antibody-based CTCL...
Na minha lista:
| Publicado no: | Oncoimmunology |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Taylor & Francis
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4570095/ https://ncbi.nlm.nih.gov/pubmed/26405593 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2015.1022306 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|